|
π
|
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
17 auth.
G. Schwartz,
A. Olsson,
M. Abt,
C. Ballantyne,
P. Barter,
J. Brumm,
B. Chaitman,
I. Holme,
D. Kallend,
Lawrence A Leiter,
...
E. Leitersdorf,
J. McMurray,
H. Mundl,
S. Nicholls,
P. Shah,
J. Tardif,
R. Wright
|
10 |
2012 |
10
π
|
|
π
|
Capecitabine as adjuvant treatment for stage III colon cancer.
26 auth.
C. Twelves,
A. Wong,
M. Nowacki,
M. Abt,
H. Burris,
A. Carrato,
J. Cassidy,
A. Cervantes,
J. Fagerberg,
V. Georgoulias,
F. Husseini,
D. Jodrell,
P. Koralewski,
H. KrΓΆning,
J. Maroun,
...
N. Marschner,
J. Mckendrick,
M. Pawlicki,
R. Rosso,
J. SchΓΌller,
J. Seitz,
B. Ε tabuc,
J. Tujakowski,
G. V. van Hazel,
J. Zaluski,
W. Scheithauer
|
10 |
2005 |
10
π
|
|
π
|
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
13 auth.
Z. Fayad,
V. Mani,
M. Woodward,
D. Kallend,
M. Abt,
T. Burgess,
V. Fuster,
C. Ballantyne,
E. Stein,
J. Tardif,
...
J. Rudd,
M. Farkouh,
A. Tawakol
|
8 |
2011 |
8
π
|
|
π
|
Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
8 auth.
G. Schwartz,
M. Abt,
W. Bao,
D. Demicco,
D. Kallend,
Michael Miller,
...
H. Mundl,
A. Olsson
|
7 |
2015 |
7
π
|
|
π¬
|
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
E. Cutsem,
P. Hoff,
J. Blum,
M. Abt,
B. Osterwalder
|
7 |
2002 |
7
π¬
|
|
π
|
Quantitative evaluation of spermatozoa ultrastructure after acupuncture treatment for idiopathic male infertility.
7 auth.
J. Pei,
E. Strehler,
U. Noss,
M. Abt,
P. Piomboni,
B. Baccetti,
...
K. Sterzik
|
6 |
2005 |
6
π
|
|
π
|
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
7 auth.
R. Camidge,
B. Reigner,
J. Cassidy,
S. Grange,
M. Abt,
E. Weidekamm,
...
D. Jodrell
|
6 |
2005 |
6
π
|
|
π
|
Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein
9 auth.
E. Niesor,
G. Schwartz,
Anne Perez,
Andrea Stauffer,
Alexandre Durrwell,
Gabriela Bucklar-Suchankova,
...
R. Benghozi,
M. Abt,
D. Kallend
|
6 |
2015 |
6
π
|
|
π¬
|
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine
H. Kletzl,
M. Giraudon,
P. Ducray,
M. Abt,
M. Hamilton,
B. Lum
|
6 |
2015 |
6
π¬
|
|
π
|
Does Vascular Calcification Accelerate Inflammation?: A Substudy of the dal-PLAQUE Trial.
10 auth.
F. Joshi,
N. Rajani,
M. Abt,
M. Woodward,
J. Bucerius,
V. Mani,
...
A. Tawakol,
D. Kallend,
Z. Fayad,
J. Rudd
|
5 |
2016 |
5
π
|
|
π
|
First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin
9 auth.
C. Schmitt,
M. Abt,
C. Ciorciaro,
D. Kling,
C. Jamois,
Eginhard Schick,
...
C. Solier,
R. Benghozi,
J. Gaudreault
|
5 |
2015 |
5
π
|
|
π’
|
Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development
K. Rufibach,
H. Burger,
M. Abt
|
5 |
2016 |
5
π’
|
